Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q6ED
|
|||
| Former ID |
DPR000129
|
|||
| Drug Name |
ASP8497
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Preclinical | [1] | |
| Company |
Astellas Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol. 2008 Jul 1;76(1):98-107. | |||
| REF 2 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.